NCT06412471View on ClinicalTrials.gov

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions
First-line Advanced NSCLC Patients
Interventions
DRUG

SSGJ-707

bispecific antibody

DRUG

carboplatin

chemotherapy

DRUG

Pemetrexed

chemotherapy

DRUG

paclitaxel

chemotherapy

DRUG

PD-1/L1

Immune checkpoint inhibitors

DRUG

Paclitaxel-albumin

chemotherapy

Trial Locations (1)

Unknown

RECRUITING

Institute of The Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY